China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing the Czech Republic firm to use its tumor-targeted fully human antibodies to develop SOT109, SOTIO’s new antibody drug conjugate (ADC) candidate. The ADC is intended for the treatment of colorectal cancer and other gastrointestinal (GI) cancers.
Agreement Terms
Under the terms of the agreement, Biocytogen will receive option exercise fees and is eligible to receive development, regulatory, and commercialization milestone payments, as well as low-single-digit royalties based on net sales. This partnership aims to leverage Biocytogen’s advanced antibody technology to accelerate the development of SOT109.
Biocytogen’s Technology
Biocytogen boasts genetically engineered proprietary RenMice platforms, which provide an off-the-shelf library of over 400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. The RenMab platforms are designed to generate high-quality monoclonal antibodies with strong immune responses, high affinity, and high specificity, without the need for additional in vitro humanization treatment. This technology significantly reduces downstream development time and costs, accelerating the development and translation of cutting-edge bispecific, multispecific antibodies, and ADC therapies.
Significance of the Partnership
This strategic partnership between Biocytogen and SOTIO Biotech highlights the potential of combining advanced antibody technology with innovative ADC development. By working together, the companies aim to bring new and effective treatments to patients with colorectal and other gastrointestinal cancers, potentially improving patient outcomes and quality of life.-Fineline Info & Tech
